
Jan 23, 2025, 12:00
Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer
Agenus shared on LinkedIn:
“Today, we announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer.
Find the details of our five ASCO GI presentations here.”
Further Reading:
Three decades of pioneering in Immune Oncology – Agenus
Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy
Botensilimab’s mechanism of action and potential in addressing treatment-resistant cancers
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 16, 2025, 13:28
Feb 16, 2025, 11:14
Feb 16, 2025, 10:56
Feb 16, 2025, 10:43
Feb 16, 2025, 09:48
Feb 16, 2025, 08:25
Feb 16, 2025, 08:19
Feb 16, 2025, 08:16
Feb 16, 2025, 08:13
Feb 16, 2025, 08:09